Results 191 to 200 of about 170,985 (294)

Physician-assisted suicide in Italy: where do we stand and where do we want to go? [PDF]

open access: yesFront Psychiatry
Turillazzi E   +3 more
europepmc   +1 more source

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma   +14 more
wiley   +1 more source

Neurology and physician-assisted suicide: glossary of definitions and terminology. [PDF]

open access: yesNeurol Sci
Solari A   +6 more
europepmc   +1 more source

Documented End‐of‐Life Preferences of People With Parkinson's Disease or Parkinsonism Across Europe

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Parkinson's disease and atypical parkinsonism are characterized by motor and non‐motor symptoms. As the disease advances, planning for end‐of‐life (EoL) care becomes increasingly important. However, consensus‐based European guidelines for advance care planning and documentation of EoL care preferences for parkinsonism are lacking ...
Bauke W. Dijkstra   +30 more
wiley   +1 more source

An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease

open access: yesMovement Disorders, EarlyView.
Complement activation is implicated in Huntington's disease; ANX005 is a potent inhibitor of component C1q. ANX005 exhibited a generally manageable safety profile with rapid reduction in C1q in the cerebrospinal fluid. Functional ability on composite Unified Huntington's Disease Rating Scale and total functional capacity was maintained, with potential ...
Rajeev Kumar   +15 more
wiley   +1 more source

Exploring the disease burden and quality of life in patients with short bowel syndrome with intestinal failure: Insights from exit interviews in the glepaglutide EASE SBS‐1 phase 3 trial

open access: yesNutrition in Clinical Practice, EarlyView.
Abstract Background A randomized, double‐blind, placebo‐controlled trial was conducted to evaluate efficacy and safety of glepaglutide in patients who have short bowel syndrome with intestinal failure (SBS‐IF). At the end of the trial, exit interviews were conducted to explore participants' experiences and to assess the impact of the disease and ...
David F. Mercer   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy